Abstract: SA-PO484

Significantly Less CMV- and BKV-Events with Everolimus-Based versus Tacrolimus-MPA Regimen in De Novo Renal Transplant Recipients: 12 Months Data on Infections from the Athena Study

Session Information

Category: Transplantation

  • 1702 Transplantation: Clinical and Translational


  • Hauser, Ingeborg Anni, University Clinic Frankfurt (UKF), Frankfurt Main, Germany
  • Junge, Martina, Novartis Pharma GmbH Germany, Nuremberg, Germany
  • Thaiss, Friedrich, University Hospital, Hamburg, Germany
  • Nashan, Björn, Bundesärztekammer , Hamburg, Germany
  • Sommerer, Claudia, University Hospital of Heidelberg, HEIDELBERG, Germany
  • Suwelack, Barbara M., None, Muenster, Germany
  • Dragun, Duska, University Hospital Charite, Campus Virchow, Berlin, Germany
  • Schenker, Peter, Ruhr-University Bochum, Bochum, Germany
  • Witzke, Oliver, University Duisburg-Essen, Essen, Germany
  • Hugo, Christian, University of Dresden, Dresden, Germany, Dresden, SN, Germany
  • Kamar, Nassim, Toulouse University Hospital, Toulouse, France
  • Merville, Pierre, PELLEGRIN HOSPITAL, Bordeaux, France

Group or Team Name

  • Athena Study Group

The ATHENA trial was designed to compare everolimus [EVR] in combination with tacrolimus [TAC] or cyclosporine A [CyA] vs. a standard of mycophenolic acid [MPA] and TAC in de novo kidney transplant [KTx] recipients.


In this 12 months [M], prospective, open-label, randomized study with 15 German and 12 French sites, 612 patients [pts] were randomized 1:1:1 at time of Tx to either EVR (3-8ng/ml M1-M12) +TAC (4-8ng/ml M1-M3; 3-5ng/ml M3-M12), or EVR (3-8ng/ml M1-M12) + CyA (75-125ng/ml M1-M3; 50-100ng/ml M3-M12) or to control TAC regimen (4-8ng/ml M1-M3; 3-5ng/ml M3-M12) with MPA. All pts continued on steroids. Herein we report M12 outcomes on infections and CMV events from ITT with 208 EVR+TAC pts, 199 EVR+CyA pts and 205 TAC+MPA pts.


From randomization to M12 total incidences of infections were 73% in EVR+TAC and 72% in EVR+CyA treated pts vs 82% in TAC+MPA pts. Whilst incidences of bacterial infections were similar between the three treatment groups (44% EVR+TAC, 43% EVR+CyA, 42% TAC+MPA) major differences were seen for viral infections with incidences of 41% in TAC+MPA vs only 26% in EVR+TAC and 12% in EVR+CyA groups. Incidence of BKV events was 23% in TAC+MPA vs 17% in EVR+TAC vs 9% in EVR+CyA pts (p<0.01). CMV events occurred two thirds less in EVR treated pts compared to TAC+MPA control group with an incidence of 21% in TAC+MPA vs 6% for EVR+TAC and 3% for EVR+CyA treatment pts (p<0.001).


ATHENA as largest European KTx study confirmed comparable efficacy and safety together with less viral infections for EVR-based treatment groups compared to TAC+MPA group. A significant, protective effect of EVR-based regimens vs CMV/BKV events was robustly confirmed.


  • Commercial Support